Publications by authors named "Yohei Tajima"

Claim this Profile
C
Clinical Outcomes of Patients with High-risk Metastatic Hormone-naïve Prostate Cancer: A 3-year Interim Analysis of the Observational J-ROCK Study.
Hideaki Miyake, Rikiya Matsumoto, Kiyohide Fujimoto, Atsushi Mizokami, Hirotsugu Uemura, Yohei Tajima

Eur Urol Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum to: Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma.
Yoshihiko Tomita, Go Kimura, Satoshi Fukasawa, Kazuyuki Numakura, Yutaka Sugiyama, Yohei Tajima

Jpn J Clin Oncol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma.
Yoshihiko Tomita, Go Kimura, Satoshi Fukasawa, Kazuyuki Numakura, Yutaka Sugiyama, Yohei Tajima

Jpn J Clin Oncol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of subsequent molecular targeted therapy after immuno-checkpoint therapy, retrospective study of Japanese patients with metastatic renal cell carcinoma (AFTER I-O study).
Yoshihiko Tomita, Go Kimura, Satoshi Fukasawa, Kazuyuki Numakura, Yutaka Sugiyama, Yohei Tajima

Jpn J Clin Oncol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and SAR Studies of Orally Active Somatostatin Receptor Subtype-2 (SSTR2) Agonists for the Treatment of Acromegaly.
Akiharu Ishida, Yohei Tajima, Yasuyuki Okabe, Takeshi Matsushita, Tetsuya Sekiguchi

ACS Chem Neurosci· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Risk Classification and Nivolumab plus Ipilimumab Combination Therapy for Treatment of Renal Cell Carcinoma].
Mototsugu Oya, Yohei Tajima, Koki Kabu

Gan To Kagaku Ryoho· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Gemilukast (ONO-6950), a Dual CysLT1 and CysLT2 Antagonist As a Therapeutic Agent for Asthma.
Satoshi Itadani, Kentaro Yashiro, Yoshiyuki Aratani, Tetsuya Sekiguchi, Atsushi Kinoshita, Yohei Tajima

J Med Chem· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of long-acting inhibitors of dipeptidyl peptidase IV.
Takashi Kondo, Isamu Sugimoto, Takahiro Nekado, Kenya Ochi, Tazumi Ohtani, Yohei Tajima

Bioorg Med Chem· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of new potent dipeptidyl peptidase IV inhibitors with enhanced ex vivo duration.
Takashi Kondo, Takahiro Nekado, Isamu Sugimoto, Kenya Ochi, Shigeyuki Takai, Yohei Tajima

Bioorg Med Chem· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis